Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
- Conditions
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 220
- Registration Number
- NCT02813486
- Locations
- 🇰🇷
Incheon St. Mary's Hospital Catholic Univ., Incheon, Bupyeong 6-dong, Bupyeong-gu,, Korea, Republic of
🇰🇷The Catholic Univ. of Korea Daejeon St.Mary's Hospital, Daejeon, Jung-Gu, Korea, Republic of
🇰🇷The Catholic Univ.of Korea Bucheon St.Mary's Hospital, Gyeonggi-do, Korea, Republic of
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 49
- Registration Number
- NCT02783482
- Locations
- 🇨🇦
Hotel Dieu de Montreal, Montréal, Quebec, Canada
🇺🇸Immuno International Research Centers, Centennial, Colorado, United States
🇨🇦CHU Ste-Justine - University of Montreal, Montreal, Quebec, Canada
Study of Idursulfase-beta (GC1111) in Hunter Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT02663024
A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 1630
- Registration Number
- NCT02658409
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 53
- Registration Number
- NCT02569372
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 317
- Registration Number
- NCT02553837
A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children
- Conditions
- Interventions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 543
- Registration Number
- NCT02541253
- Locations
- 🇰🇷
Changwon Fatima Hospital, Changwon, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷The Catholic Univ. of Korea Daejeon St. Mary's Hospital, Daejeon, Korea, Republic of
Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 39
- Registration Number
- NCT02367638
To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 376
- Registration Number
- NCT02361866
- Locations
- 🇰🇷
Incheon St. Mary's Hospital Catholic Univ., Incheon, Bupyeong 6-dong, Bupyeong-gu,, Korea, Republic of
Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 226
- Registration Number
- NCT02360514